Status:

COMPLETED

Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor

Lead Sponsor:

Stimvia s.r.o.

Conditions:

Parkinson's Disease

Essential Tremor

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

This is a 6-week exploratory clinical study, designed to test whether treatment with peroneal electrical trans-cutaneous stimulation can have a beneficial effects on symptoms associated with Parkinson...

Detailed Description

This is a 6-week, open-label, single site clinical study designed to test whether treatment with peroneal electrical trans-cutaneous stimulation (eTNM) can have a beneficial effects on symptoms associ...

Eligibility Criteria

Inclusion

  • 18 years of age
  • Competent and willing to provide written, informed consent to participate in the study
  • Stable dose of any chronic medications, if applicable, for 30 days prior to study entry
  • Willing to comply with study protocol requirements
  • Subject agrees not to participate in another study from 30 days prior the screening visit until the final study visit
  • For subjects with PD:
  • Bradykinesia in "on" period based on clinical assessment Rigidity in "on" period based on clinical assessment Hand/arm exhibiting tremor (resting and/or intentional and/or postural) ≥ grade 1 as assessed by the MDS-UPDRS tremor score in "on" period
  • • For subjects with ET: Visible hand/arm and/or foot/leg tremor (resting and/or intentional and/or postural) ≥ grade 1 as assessed by the TETRAS

Exclusion

  • Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator
  • Suspected or diagnosed epilepsy or other seizure disorder
  • Severe degree of disability or dependence in daily activities \>grade 3 as measured by modified Rankin Scale (mRS)
  • Presence of clinical signs or diagnosis of dementia
  • Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
  • Presence of clinical signs of peripheral neuropathy on lower limbs
  • Presence of chorea and/or dyskinesia
  • Clinical symptoms or diagnosis of major depressive disorder
  • Presence of any other neurodegenerative disease. These may include multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.
  • Botulinum toxin injection within 6 months prior to study enrollment
  • Participation in another interventional clinical trial in the last 30 days, which may confound the results of this study, unless approved by the Sponsor
  • Subject is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control (these are methods with a failure quotient of \<1% year such as hormonal implants, injectable contraceptives, oral contraceptives of combination type, intra-uterine pessaries restricted to hormone contraceptive coil, sexual abstinence or vasectomy of the partner). The pregnancy test in urine at both Visits 1 and 2 needs to be negative in women of childbearing potential.
  • Subjects unable to communicate effectively with the investigator and staff
  • Life expectancy less than 6 months
  • Subject with active malignant disease
  • Subject with alcohol (more than 100 mg ethanol per day) or drug abuse during the recruitment and during the trial course
  • Subject who, in the opinion of the physician, may interfere with optimal participation in the clinical trial or may pose a risk to the subject
  • Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol

Key Trial Info

Start Date :

September 15 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2024

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT06036368

Start Date

September 15 2023

End Date

June 30 2024

Last Update

August 21 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cerebrovaskulární poradna s.r.o.

Ostrava, Czechia, 70200